secwatch.observer — SEC 8-K summary
======================================

Issuer:     ArriVent BioPharma, Inc. (AVBP)
CIK:        0001868279
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001104659-25-108839
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ArriVent reports Q3 net loss $130.8M; cash $305.4M funds into mid-2027
----------------------------------------------------------------------

- Net loss $130.8M for nine months ended Sep 30, 2025, up from $59.9M in 2024, driven by R&D spend including $40M upfront for ARR-217.
- Cash and investments $305.4M as of Sep 30, 2025; expected to fund operations into mid-2027.
- R&D expense $121.2M (incl. $40M upfront for ARR-217 license) vs $58.8M prior year; G&A $17.5M vs $11.8M.
- Appointed Brent S. Rice as Chief Commercial Officer; Phase 1b firmonertinib data in EGFR PACC mutant NSCLC presented at WCLC.
- Phase 3 ALPACCA trial for PACC mutant NSCLC first patient enrollment expected Q4 2025; topline FURVENT Phase 3 data in exon 20 insertion NSCLC projected early 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1868279/000110465925108839/0001104659-25-108839-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1868279/000110465925108839/avbp-20251110x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-108839

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer